Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound

Rizzitelli, Silvia; Giustetto, Pierangela; Cutrìn, Juan Carlos; Castelli, Daniela Delli; Boffa, Cinzia; Ruzza, Marta; Menchise, Valeria; Molinari, Filippo; Aime, Silvio; Terreno, Enzo

doi:10.1016/j.jconrel.2015.01.028

Cited by 55 publications

(41 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 Finally, the organs belonging to the excretory system (kidneys and bladder, Figure S2) were highlighted by a T 1 -contrast increase only immediately after the injection (bolus passage), thus excluding the renal filtration of the paramagnetic probe and confirming the good in vivo stability of the theranostic nanoparticles.…”

Section: Accepted M Manuscriptmentioning

confidence: 81%

First in vivo MRI study on theranostic dendrimersomes

Filippi

Catanzaro

Patrucco

et al. 2017

Journal of Controlled Release

View full text Add to dashboard Cite

Amphiphilic Janus-dendrimers are able to self-assemble into nanosized vesicles named dendrimersomes. We recently synthesized the 3,5-C 12 -EG-(OH) 4 dendrimer that generates dendrimersomes with very promising safety and stability profiles, that can be loaded with different contrast agents for in vivo imaging. In this contribution, nanovesicles were loaded with both the Magnetic Resonance Imaging (MRI) reporter GdDOTAGA(C 18 ) 2 and the glucocorticoid drug Prednisolone Phosphate (PLP), in order to test their effective potential as theranostic nanocarriers on murine melanoma tumour models. The incorporation of GdDOTAGA(C 18 ) 2 into the membrane resulted in dendrimersomes with a high longitudinal relaxivity (r 1 = 39.1 mM -1 s -1 , at 310 K and 40MHz) so that, after intravenous administration, T 1 -weighted MRI showed a consistent contrast enhancement in the tumour area. Furthermore, the nanovesicles encapsulated PLP with good efficiency and displayed anti-tumour activity both in vitro and in vivo, thus enabling their practical use for biomedical theranostic applications.

show abstract

Section: Accepted M Manuscriptmentioning

confidence: 81%

First in vivo MRI study on theranostic dendrimersomes

Filippi

Catanzaro

Patrucco

et al. 2017

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…5 Unlike other stimuli, including pH, temperature, and enzymatic degradation, US offers precise control over spatiotemporal drug release and drug transport into solid tumors. 6–8 The US intensity is easily adjustable from low intensities used for diagnosis (<720 mW/cm 2 ) to high-intensity therapeutic irradiation (up to 10 5 W/cm 2 ) for tumor treatment. 9 …”

mentioning

confidence: 99%

Theranostic Multilayer Capsules for Ultrasound Imaging and Guided Drug Delivery

et al. 2017

View full text Add to dashboard Cite

Despite the accessibility of ultrasound, the clinical potential of ultrasound-active theranostic agents has not been fully realized because it requires combining sufficient imaging contrast, high encapsulation efficiency, and ultrasound-triggered release in one entity. We report on theranostic polymer microcapsules composed of hydrogenbonded multilayers of tannic acid and poly(N-vinylpyrrolidone) that produce high imaging contrast and deliver the anticancer drug doxorubicin upon low-power diagnostic or high-power therapeutic ultrasound irradiation. These capsules exhibit excellent imaging contrast in both brightness and harmonic modes and show prolonged contrast over six months, unlike commercially available microbubbles. We also demonstrate low-dose gradual and high-dose fast release of doxorubicin from the capsules by diagnostic (~100 mW/cm2) and therapeutic (>10 W/cm2) ultrasound irradiation, respectively. We show that the imaging contrast of the capsules can be controlled by varying the number of layers, polymer type (relatively rigid tannic acid versus more flexible poly(methacrylic acid)), and polymer molecular weight. In vitro studies demonstrate that 50% doxorubicin release from ultrasound-treated capsules induces 97% cytotoxicity to MCF-7 human cancer cells, while no cytotoxicity is found without the treatment. Considering the strong ultrasound imaging contrast, high encapsulation efficiency, biocompatibility, and tunable drug release, these microcapsules can be used as theranostic agents for ultrasound-guided chemotherapy.

show abstract

“…Studies utilizing liposomal-based NPs for PCa and BC theranostic techniques are few [238,239,240,241,242,243,244,245,246,247], although applications for therapy or imaging alone are significantly more frequently published [248,249,250,251,252,253,254,255,256,257,258,259,260,261]. For example, Yeh et al recently published results from experiments investigating peptide-conjugated liposomal NPs in a theranostic approach for PCa.…”

Section: Nanoparticles For Prostate and Breast Cancermentioning

confidence: 99%

Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer

Elgqvist

2017

IJMS

View full text Add to dashboard Cite

Prostate and breast cancer are the second most and most commonly diagnosed cancer in men and women worldwide, respectively. The American Cancer Society estimates that during 2016 in the USA around 430,000 individuals were diagnosed with one of these two types of cancers, and approximately 15% of them will die from the disease. In Europe, the rate of incidences and deaths are similar to those in the USA. Several different more or less successful diagnostic and therapeutic approaches have been developed and evaluated in order to tackle this issue and thereby decrease the death rates. By using nanoparticles as vehicles carrying both diagnostic and therapeutic molecular entities, individualized targeted theranostic nanomedicine has emerged as a promising option to increase the sensitivity and the specificity during diagnosis, as well as the likelihood of survival or prolonged survival after therapy. This article presents and discusses important and promising different kinds of nanoparticles, as well as imaging and therapy options, suitable for theranostic applications. The presentation of different nanoparticles and theranostic applications is quite general, but there is a special focus on prostate cancer. Some references and aspects regarding breast cancer are however also presented and discussed. Finally, the prostate cancer case is presented in more detail regarding diagnosis, staging, recurrence, metastases, and treatment options available today, followed by possible ways to move forward applying theranostics for both prostate and breast cancer based on promising experiments performed until today.

show abstract

Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound

Cited by 55 publications

References 62 publications

First in vivo MRI study on theranostic dendrimersomes

First in vivo MRI study on theranostic dendrimersomes

Theranostic Multilayer Capsules for Ultrasound Imaging and Guided Drug Delivery

Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer

Contact Info

Product

Resources

About